Please use this identifier to cite or link to this item:
|Title:||Treatment of primary cancer in metastatic hormone-sensitive prostate cancer.||Austin Authors:||Lim, Kylie Y-Y;Alberto, Matthew;Ranasinghe, Weranja||Affiliation:||Department of Urology, Monash Health, Casey.;Department of Surgery.
|Issue Date:||1-Dec-2023||Date:||2023||Publication information:||Current Opinion in Supportive and Palliative Care 2023-12-01; 17(4)||Abstract:||Recently, there has been emerging interest in the treatment of primary tumours in metastatic prostate cancer based on major trials that have provided evidence for radiation therapy and cytoreductive radical prostatectomy. Preclinical studies have further established the molecular features of metastatic disease that provide a rationale for primary treatment. Several randomised controlled trials and other prospective studies have demonstrated a benefit in overall survival, predominantly in low-volume disease. Advancements in precision medicine also offer insight into improving selection, staging and monitoring. In this review, the authors highlight and review recent data on emerging and established treatment options and shift towards personalised medicine for hormone-sensitive metastatic prostate cancer.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/33964||DOI:||10.1097/SPC.0000000000000676||ORCID:||Journal:||Current Opinion in Supportive and Palliative Care||PubMed URL:||37788147||ISSN:||1751-4266||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 10, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.